Drug Ups Response Rate in Refractory Hepatitis C (CME/CE)

(MedPage Today) — The protease inhibitor, telaprevir (Incivek), markedly improved response rates in patients with hard-to-treat hepatitis C virus (HCV) infection, compared with standard therapy, researchers in two different trials reported.

Post a Comment

Comments are closed.